Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Kidney Transplant
Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 06 Jun 2019
Price : $35 *
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Proof of concept; Therapeutic Use
- 30 May 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 18 Dec 2018 Planned initiation date changed from 15 Oct 2018 to 15 Feb 2019.
- 20 Aug 2018 New trial record